CATAFLAM
LOE ApproachingNDAORALTABLET
Approved
Nov 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAFLAM is an oral tablet small-molecule NSAID approved by Novartis in November 1993. The drug's specific mechanism of action and approved indications are not detailed in available data, but as an NSAID it likely targets inflammation and pain. It is formulated as an immediate-release oral tablet for systemic delivery.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team contraction and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CATAFLAM currently has zero linked job openings, reflecting its LOE-approaching status and reduced commercial activity. Career opportunities are primarily in defensive roles managing brand erosion, generic transition, and maintenance of existing market share rather than growth-oriented positions.
Brand ManagerGeneric Transition Manager
Worked on CATAFLAM at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.